First-on-Target Antibody Drug Conjugate for Treatment of Ovarian Cancer
Preclinical Platform Advancing Towards IND
Novel MOA - First-on-target ADC with effective internalisation and payload delivery, developed over 6 years.
Validated indications - In ovarian and other solid-tumour models.
Pre-Clinical Efficacy - Effective cytotoxicity in human cell models and in mouse xenograft models.
Safety evaluation - Mouse toxicology complete with a clean profile; rat study planned as part of standard IND-enabling steps.
Regulatory Advice – Medicines Discovery Catapult programme commissioned; IND-enabling roadmap delivered in collaboration with Boyds and Apconix.
Why It Matters
-
Broad Patient Coverage
Target highly expressed in high-grade serous ovarian cancer
-
Low Off-Tumour Effects
Minimal expression in healthy tissue, improving tolerability.
-
ADC Suitable Biology
Confirmed internalisation enables efficient payload delivery.
Building the Next Generation of ADCs
Our focus is to complete IND-enabling studies and prepare for first-in-human evaluation of our lead ADC.
We’re seeking strategic investment and partnerships to accelerate this next stage of development — advancing a highly selective, first-on-target ADC with the potential to transform treatment for solid tumours.
Pipeline
Contact us.
We welcome enquiries from investors, partners, and collaborators interested in our first-on-target ADC programme.
Share a few details below, and our team will get back to you shortly.